|
|
|
|
|
|
Companies > Preclinical
|
|
|
Thermalin Diabetes has identified a portfolio of novel heat-stable and fast-acting insulin analogues. The company’s technology is based upon insights into structural factors leading to the irreversible fibrillation and inactivation of insulin in aqueous solution.
Funders:
JumpStart, Angels
|
|
|
|
|